| Download a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
Lundbeck aspires to become one of the world's leading specialist suppliers of
drugs to treat CNS diseases. This report provides a full review of the
company's activities together with sales forecasts for key products to 2010.
Lundbeck is a research-based pharmaceutical company which, since 1989, has
concentrated on a single core therapeutic area, namely the development and
sale of pharmaceuticals for the treatment of diseases of the central nervous
system. To date, the company has largely focused on drugs for psychiatry and
neurology, however it has broader ambitions, namely to become one of the
world's leading specialist suppliers of drugs to treat CNS diseases.
In February 2004, Lundbeck entered into one of its biggest partnerships to
date, after signing an agreement with Merck & Co for the development and
commercialisation of gaboxadol in the US. This was extended in June 2004 to
include Japan, giving Lundbeck a competent partner in the two largest CNS
markets.
In addition, Lundbeck maintained a high level of research funding relative to
the industry average at DKr 1,782 million in 2005 (+0.3 per cent), accounting
for 19.6 per cent of total revenue. Lundbeck expects to be able to continue
this level of funding in years to come.
TABLE OF CONTENTS
Principal Operating Results
Latest Results
EXECUTIVE SUMMARY
- Introduction
- Financial Performance 2005
- Sales and Market Position
- Income
- Sales, Costs and Operating Income
- Expenditure
- Capital Expenditure
- Capital Expenditure By Geographical Area
- Capital Expenditure By Geographical Area, 2005
- R&D Expenditure
- Geographic Performance
- Sales By Geographical Area
- Sales By Geographical Area, 2005
- Assets By Geographical Area
- Assets By Geographic Area, 2005
- Company Strategy
- Key Mergers, Acquisitions and
- Divestitures
- Acquisitions
- Divestitures
- Key Agreements
- Production
- Employees
- Employees By Function (Year End)
- Employees and Productivity (Average)
- Product/R&D Overview
- Key Products
- Recent Product Launches
- Recent Product Approvals
- R&D Strategy
- R&D Pipeline Overview
- Sales Forecasts
- Sales of Current Top Five Products (2000A-2010E)
- Outlook/Conclusions
PRODUCT PORTFOLIO / RESEARCH & DEVELOPMENT
- Major Products, Therapeutic Areas and Sales
- Sales By Product Area
- Top Selling Products, 2005
- Central Nervous System - Products
- Major Launched Products
- Antidepressants
- Cipralex/Lexapro
- Sales
- Licensees
- Key Markets/Indications
- Further Development
- Competitor Products
- Patents
- Generic Competition/Lawsuits
- Sales Forecast
- Cipralex Sales (2002A-2010E)
- Clinical Trial Results - Depression
- Clinical Trial Results - GAD
- Clinical Trial Results - Obsessive-Compulsive Disorder
- Cipramil/Celexa/Cipram/Seropram
- Sales
- Markets/Indications
- Licensees
- New Formulations
- Competitor Products
- Generic Competition
- Sales Forecast
- Cipramil Sales (2000A-2010E)
- Deanxit
- Noritren/Noritrilen/Sensaval
- Saroten/Sarotex/Redomex
- Tymelyt
- Others
- Antipsychotics
- Cisordinol/Clopixol/Ciatyl-Z
- Fluanxol/Depixol
- Lyogen
- Serdolect/Serlect
- Markets/Indications
- Licensees
- Taxilan
- Truxal/Truxaletten
- Anti-Parkinson's Disease
- Agilect/Azilect
- Sales
- Markets/Indications
- Further Development
- Clinical Trial Results
- Other
- Almogran/Axert
- Ebixa
- Mode of Action
- Sales
- Key Markets/Indications
- US Development
- Further Development
- Competitor Products
- Sales Forecast
- Ebixa Sales (2002A-2010E)
- Keppra
- Sonata
- Central Nervous System - R&D
- R&D Pipeline
- Antipsychotics
- Bifeprunox (DU127090)
- Lu 31-130
- Antidepressants
- Lu AA21004
- Lu AA24530
- Lu AA34893
- Other
- Desmoteplase
- Gaboxadol
- MCH-1 receptors
- Neuropeptide Y and galanin receptors
- Discontinued
- Glatiramer oral
- CEP-1347
- Etilevodopa (TV 1203)
- Central Nervous System - Summary
- Growth Potential
- Limiting Factors
APPENDIX 1 - FINANCIAL PERFORMANCE
- Full Year Results 2005
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- R&D Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity
APPENDIX 2 - KEY AGREEMENTS
- Cephalon Inc
- Cue Biotech
- Forest Laboratories Inc
- 7th March 1996
- 27th March 1998
- Johnson & Johnson
- 29th September 2000
- 20th November 2002
- Merck & Co
- 10th February 2004
- 28th June 2004
- Merz + Co GmbH & Co
- PAION AG
- Solvay
- Teva Pharmaceutical Industries Ltd
- Licensed-in
- Licensed-out
- Co-promotion/Co-marketing
APPENDIX 3 - INFRASTRUCTURE
- Manufacturing Facilities
- Research & Development Facilities
APPENDIX 4 - KEy PHARMACEUTICAL SUBSIDIARIES AND ASSOCIATED COMPANIES
APPENDIX 5 - PRODUCT INDEX
|
